医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nitto’s ND-L02-s0201:RNAi Anti-Fibrosis Drug for the Treatment of Liver Fibrosis Granted FDA Fast Track Designation

2015年11月20日 PM11:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Japan’s leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) reported preliminary results from their ongoing Phase1b/2 studies during The Liver Meeting® 2015, San Francisco. The Phase1b/2 clinical trial was designed to assess the safety, pharmacokinetics (PK), and biological activity of ND-L02-s0201, a targeted siRNA lipid nanoparticle (LNP), in patients with liver fibrosis. The interim results indicated that ND-L02-s0201 was well tolerated in advanced fibrosis patients and histological improvement of fibrosis was observed.

In addition, ND-L02-s0201 was granted two FDA Fast Track designations for both NASH and HCV liver fibrosis indications in October. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Nitto continues to make significant efforts towards delivering new drugs for fibrosis and other intractable diseases to help patients in need.

With the brand slogan of “Innovation for Customers”, Nitto is committed to creating new value in the areas of Green (environment), Clean (new energy), and Fine (life sciences), looking forward to the company’s 100th anniversary in 2018 and beyond.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151120005187/en/

CONTACT

Nitto Denko Corporation
Toshiaki Minagawa / Rie Miura,
+81-6-7632-2101
Brand Strategy Dept., Corporate Strategy Management
Div.
FAX: +81-6-7632-2568
communication_group@nitto.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
  • 2020年迪拜世界博览会启动 Expo Live:一个造福社会的创新与合作项目
  • Washington University in St. Louis to Host Major Forum on Aging; Gathering in Shanghai Brings Together Greater China University Research Partners to Address Unprecedented Global Social Challenge
  • 圣路易斯华盛顿大学将举办老龄化问题大型论坛;在上海举行的论坛将聚集大中华区大学研究合作伙伴,讨论应对前所未有的全球性社会挑战
  • Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea